Methotrexate Locally Released from Poly(ε-Caprolactone) Implants: Inhibition of the Inflammatory Angiogenesis Response in a Murine Sponge Model and the Absence of Systemic Toxicity

Journal of Pharmaceutical Sciences

Volumn 104, Issue 11, 2015, Pages 3731-3742

  De Oliveira, Leandro Gonzaga ^a   Figueiredo, Letícia Aparecida ^a   Fernandes Cunha, Gabriella Maria ^b   De Miranda, Marina Barcelos ^a   MacHado, Laser Antônio ^a   Da Silva, Gisele Rodrigues ^c   De Moura, Sandra Aparecida Lima ^a  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO JOÃO DEL REI   (Brazil)

Author keywords

biodegradable polymers; biomaterials; controlled release; controlled release delivery; drug delivery; polymer; polymeric drug carrier; polymeric drug delivery systems; targeted drug delivery; toxicology

Indexed keywords

COLLAGEN; CREATININE; HEMOGLOBIN; INTERLEUKIN 6; METHOTREXATE; MYELOPEROXIDASE; N ACETYL BETA GLUCOSAMINIDASE; POLYCAPROLACTONE; TUMOR NECROSIS FACTOR ALPHA; UREA; ACETYLGLUCOSAMINIDASE; ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; DRUG IMPLANT; PEROXIDASE; POLYESTER; TUMOR NECROSIS FACTOR; CYTOKINE; DELAYED RELEASE FORMULATION; IMMUNOSUPPRESSIVE AGENT;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CONTROLLED STUDY; DRUG IMPLANT; DRUG RELEASE; ENZYME ACTIVITY; EQUIPMENT DESIGN; HEMOGLOBIN BLOOD LEVEL; LIVER TOXICITY; LOCAL THERAPY; MACROPHAGE; MALE; NEPHROTOXICITY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; TISSUE GROWTH; TOXICITY TESTING; VASCULARIZATION; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; INFLAMMATION; METABOLISM; MOUSE; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; TISSUE DISTRIBUTION; DELAYED RELEASE FORMULATION; PROSTHESES AND ORTHOSES;

ACETYLGLUCOSAMINIDASE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL PROLIFERATION; COLLAGEN; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; DRUG LIBERATION; INFLAMMATION; INTERLEUKIN-6; MACROPHAGES; MALE; METHOTREXATE; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; NEUTROPHIL INFILTRATION; PEROXIDASE; POLYESTERS; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR-ALPHA; CYTOKINES; DELAYED-ACTION PREPARATIONS; IMMUNOSUPPRESSIVE AGENTS; PROSTHESES AND IMPLANTS;

EID: 84944096906     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24569     Document Type: Article

References (42)

1. Arroyo AG, Iruela-Arispe ML,. 2010. Extracellular matrix, inflammation, and the angiogenic response. Cardiovasc Res 86: 226-235.
2. Sen CK,. 2009. Wound healing essentials: Let there be oxygen. Wound Repair Regen 17: 1-18.
3. Koh TJ, DiPietro LA,. 2011. Inflammation and wound healing: The role of the macrophage. Expert Rev Mol Med 11: 13-23.
4. Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, Jonckx B, Tian YM, Lanahan AA, Pollard P, Ruiz de Almodovar C, De Smet F, Vinckier S, Aragonés J, Debackere K, Luttun A, Wyns S, Jordan B, Pisacane A, Gallez B, Lampugnani MG, Dejana E, Simons M, Ratcliffe P, Maxwell P, Carmeliet P,. 2009. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136: 839-851.
5. Nesher G, Osborn TG, Moore TL,. 1996. In vitro effects of methotrexate on polyamine levels in lymphocytes from rheumatoid arthritis patients. Clin Exp Rheumatol 14 (4): 395-399.
6. Lee SS, Hughes P, Ross AD, Robinson MR,. 2010. Biodegradable implants for sustained drug release in the eye. Pharm Res 27: 2043-2053.
7. Van E, De AE, Roland FJM, Laan HJ, Roney ADA,. 1998. Methotrexate in rheumatoid arthritis: An update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 27 (5): 277-292.
8. Dong X, Chen N, Xie L, Wang S,. 2006. Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal drug delivery system of all-trans retinoic acid. Retina 26: 210-213.
9. Wang D, Miller SC, Liu X-M, Anderson B, Wang XS, Goldring SR,. 2007. Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis. Arthritis Res Ther 9 (1): R2.
10. Moura SAL, Lima LDC, Andrade SP, Silva-Cunha A, Oréfice RL, Ayres E, Silva GR,. 2011. Local drug delivery system: Inhibition of inflammatory angiogenesis in a murine sponge model by dexamethasone-loaded polyurethane implants. J Pharm Sci 100 (7): 2886-2895.
11. Jiménez-Gõmez B, González-Montpetit M, Calduch AF, Bañuelos AO, Valsero SF,. 2015. Effects of ozurdex on intraocular pressure. A real life clinical practice study. Arch Soc Esp Oftalmol 25. pii: S0365-6691(15)00043-X [Epub ahead of print]
12. Pereira, AF, Pereira LGR, Barbosa LAO, Fialho SL, Pereira BG, Patrício PSO, Pinto FCH, Silva GR,. 2013. Efficacy of methotrexate-loaded poly(ε-caprolactone) implants in Ehrlich solid tumor-bearing mice. Drug Deliv 20 (3-4): 168-179.
13. Goulian M, Bleibe B, Tseng BY,. 1980. Methotrexate-induced misincorporation of uracil into DNA. Proc Acad Sci USA 77: 1956-1960.
14. Ackland SP, Schilsky RL,. 1987. High-dose methotrexate: A critical reappraisal. J Clin Oncol 5: 2017-2031.
15. Cheng L, Shengrong G, Weiping W,. 2009. Characterization and in vitro release of praziquantel from poly(ε-caprolactone) implants. Int J Pharm 377: 112-119.
16. Drabkin DL, Austin JH,. 1935. Preparations from washed blood cells: Nitric oxide hemoglobin and sulphemoglobin. J Biol Chem 112: 51-56.
17. Plunkett ML, Hailey JA,. 1990. An in vivo quantitative angiogenesis model using tumor cells entrapped in alginate. Lab Invest 62 (4): 510-517.
18. Belo AV, Barcelos LS, Ferreira MAND, Teixeira MM, Andrade SP,. 2004. Inhibition of inflammatory angiogenesis by distant subcutaneous tumor in mice. Life Sci 74: 2827-2837.
19. Ferreira MA, Barcelos LS, Teixeira MM, Bakhle YS, Andrade SP,. 2007. Tumor growth, angiogenesis and inflammation in mice lacking receptors for platelet activating factor (PAF). Life Sci 81: 210-217.
20. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY,. 2004. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 114: 438-446.
21. Campos PP, Bakhle YS, Andrade SP,. 2008. Mechanisms of wound healing responses in lupus-prone New Zealand White mouse strain. Wound Repair Regen 16: 416-424.
22. Szekanecz Z, Besenyei T, Paragh G, Koch AE,. 2009. Angiogenesis in rheumatoid arthritis. Autoimmunity 42 (7): 563-573.
23. Trindade ATM., 2012. Estabelecimento de valores de referência para parâmetros hematolõgicos e bioquímicos e avaliação do perfil imunolõgico de linhagens de camundongos produzidas nos biotérios do Centro de Pesquisas René Rachou 147 f. Tese de mestrado/FIOCRUZ-Minas e do Centro de Criação de Animais de Laboratõrio / FIOCRUZ.
24. Palakurthi NK, Correa ZM, Augsburger JJ, Banerjee RK,. 2011. Toxicity of a biodegradable microneedle implant loaded with methotrexate as a sustained release device in normal rabbit eye: A pilot study. J Ocul Pharmacol Ther 27 (2): 151-156.
25. Williams AS, Camilleri JP, Goodfellow RM, Williams BD,. 1996. A single intra-articular injection of liposomally conjugated methotrexate suppresses joint inflammation in rat antigen-induced arthritis. Br J Rheumatol 35 (8): 719-724.
26. Yamaoka KA, Miyasaka N, Kashiwazaki S,. 1991. L-tryptophan contaminant "peak E" and interleukin-5 production from T cells. Lancet 7 (338)(8780): 1468.
27. Shaker OG, Khairallah M, Rasheed HM, Abdel-Halim MR, Abuzeid OM, El Tawdi AM, El Hadidi HH, Ashmaui A,. 2013. Antiangiogenic effect of methotrexate and PUVA on psoriasis. Cell Biochem Biophys 67 (2): 735-742.
28. Dolhain RJEM, Tak PP, Dijkmans BAC, Kuiper P, Breedveld FC, Miltenburg AMM,. 1998. Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br J Rheumatol 37: 502-508.
29. Dalmarco EM, Fröde TS, Medeiros YS,. 2002. Effects of methotrexate upon inflammatory parameters induced by carrageenan in the mouse model of pleurisy. Mediators Inflamm 11 (5): 299-306.
30. Gensel JC, Zhang B,. 2015. Macrophage activation and its role in repair and pathology after spinal cord injury. Brain Res 8. pii: S0006-8993(14)01752-1 [Epub ahead of print]
31. Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, Yao Y,. 2014. Targeting interleukin-6 in inflammatory autoimmune diseases. Pharmacol Ther 141 (2): 125-139.
32. Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, Nishimoto N,. 2003. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48 (6): 1521-1529.
33. Borchers AT, Keen CL, Gershwin ME,. 2004. The use of methotrexate in rheumatoid arthritis. Semin Arthritis Rheum 34 (1): 465-483.
34. Yoshida M, Sakuma-Mochizuki J, Abe K, Arai T, Mori M, Goya S, Matsuoka H, Hayashi S, Kaneda Y, Kishimoto T,. 1999. In vivo gene transfer of an extracellular domain of platelet-derived growth factor beta receptor by the HVJ-liposome method ameliorates bleomycin-induced pulmonary fibrosis. Biochem Biophys Res Commun 265: 503-508.
35. Romão VC, Canhão H, Fonseca JE,. 2013. Old drugs, old problems: Where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs ? BMC Med 11: 17.
36. Dalaklioglu S, Genc GE, Aksoy NH, Akcit F, Gumuslu S,. 2013. Resveratrol ameliorates methotrexate-induced hepatotoxicity in rats via inhibition of lipid peroxidation. Hum ExpToxicol 32 (6): 662-671.
37. Vardi N, Parlakpinar H, Ates B, Cetin A, Otlu A,. 2013. The protective effects of Prunusarmeniaca L (apricot) against methotrexate-induced oxidative damage and apoptosis in rat kidney. J Physiol Biochem 69 (3): 371-381.
38. Babiak RMV, Campello AP, Carnieri EGS, Oliveira MBM,. 1998. Methotrexate: Pentose cycle and oxidative stress. Cell Biochem Funct 16: 283-293.
39. Lieberthal W, Koh JS, Levine JS,. 1998. Necrosis and apoptosis in acute renal failure. Semin Nephrol 18: 505-518.
40. Widemann BC, Adamson PC,. 2006. Understanding and managing methotrexate nephrotoxicity. Oncologist 11 (6): 694-703.
41. Lim AYN, Gaffney K, Scott DGI,. 2005. Methotrexate-induced pancytopenia: Serious and under-reported? Our experience of 25 cases in 5 years. Rheumatology 44 (80): 1051-1055.
42. +Treg cells and inducing Th1 to Th2 shift in both cells and cytokines. Biomed Pharmacother 64 (7): 463-471.